Alternatives to Layla

A menopause-focused program that bills insurance for eligible visits. The visit is covered in network or $250 self-pay, and the medication is billed separately from $164 per four-week supply — both figures published. It's built for perimenopause, not the postpartum year.

• $21.33 less per month on average than Layla
• serves all 50 states, where Layla lists Not stated on the site
• offers FDA-approved brand pens, not just compounded

The widest menu on our list — injections, sublingual lozenges, daily drops, four brand-name pens and the approved oral GLP-1 — with three compounding pharmacies named, prices published for every plan length, and cancellation terms among the most restrictive we have read.

• serves all 50 states, where Layla lists Not stated on the site
• offers FDA-approved brand pens, not just compounded
• has an oral option if you would rather not inject

Price-first and nationwide: flat, all-inclusive compounded pricing at $175 and $235 month to month, down to $99 and $125 on a 12-month plan — strong if you read the prepay fine print.

• $24 less per month on average than Layla
• serves all 50 states, where Layla lists Not stated on the site
• scores 80/100 against Layla's 40

Semaglutide: $199/mo; tirzepatide: Starting at $399/mo. Oral semaglutide starts at $299 and oral tirzepatide at $399; confirm your dose, plan length and cancellation terms.

• serves all 50 states, where Layla lists Not stated on the site
• has an oral option if you would rather not inject
• scores 78/100 against Layla's 40

Four named pharmacies, a named prescribing partner and brand-name Wegovy, Zepbound and Ozempic alongside the compounded line — that is a fuller disclosure than most providers we review manage. Compounded GLP-1 injections start at $179 a month and daily dissolvable tablets at $249, and the price attaches to the form rather than the molecule: the product page never says whether you are getting semaglutide or tirzepatide, and the terms confirm both are in scope. Two things deserve a mother's attention before she enrolls. The brand products are priced as a membership plus an undisclosed medication cost, and that membership is quoted at two different figures on one page, $99 beside Zepbound and Wegovy and $171 beside Ozempic. And the terms state that if a provider decides a different molecule suits you better, staying enrolled is itself your consent to the switch and the charges continue. It also discloses, unusually plainly, that people shown in its advertising may be actors or artificial intelligence rather than clinicians.

• $20 less per month on average than Layla
• serves all 50 states, where Layla lists Not stated on the site
• offers FDA-approved brand pens, not just compounded

FDA warning letter #728279 (June 2026), which names Eden's website — read that first. Then read the price twice: the advertised $99 is medication alone, with a required $99-a-month membership on top.

• $1 less per month on average than Layla
• serves all 50 states, where Layla lists Not stated on the site
• offers FDA-approved brand pens, not just compounded

Three pages of this site quote three different prices for the same treatment: the homepage says semaglutide starts at $169 a month, the packages page shows $169 for month one and $199 from month two, and the semaglutide page says the program "typically ranges from $200-$550 per month" — a ceiling nothing on the site comes near. The packages page is the one to trust, and to its credit every plan total on it recomputes to the exact dollar. It also, on the oral semaglutide cards, tells you that what you will receive is tirzepatide.

• serves all 50 states, where Layla lists Not stated on the site
• offers FDA-approved brand pens, not just compounded
• has an oral option if you would rather not inject

Semaglutide: $179/mo monthly; $99/mo with $1,188 annual prepay; tirzepatide: $249/mo monthly; $159/mo with $1,908 annual prepay. Annual prepayment lowers the equivalents to $99 and $159 per month, while month-to-month plans cost $179 and $249.

• $20 less per month on average than Layla
• serves all 50 states, where Layla lists Not stated on the site
• offers FDA-approved brand pens, not just compounded

Semaglutide: $189/mo monthly ($149/mo on a 6-month plan); tirzepatide: $289/mo monthly ($249/mo on a 6-month plan). The lower $149 and $249 figures require six-month plans; the optional $99 genetic test is additional.

• $10 less per month on average than Layla
• serves all 50 states, where Layla lists Not stated on the site
• has an oral option if you would rather not inject